Filing Flows › Arbutus Biopharma (ABUS) › Q2 2026
Arbutus Biopharma (ABUS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Arbutus Biopharma (ABUS) reported revenue of $1.0M for the second quarter 2026 (Q2 2026), -91% from a year earlier and -99% from the quarter before. Operating margin was -588.2%, net loss $5.1M (507.2% of revenue).
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | -99% | -91% |
| Operating profit | −$6.0M | -104% | -501% |
| Net earnings | −$5.1M | -103% | -304% |
| Operating cash flow | −$6.0M | — | — |
What changed
Revenue was $1.0M in Q2 2026, down 91% year over year and down 99% from the previous quarter. Revenue from collaborations and licenses was the largest line at 62% of revenue. Collaborations and licenses lost $10.0M year over year (down 98%), 103% of the total change.
Operating costs exceeded revenue by $6.0M, an operating margin of -588.2%. Total costs fell 25% while revenue fell 91%. The fastest-growing cost line was General & admin (+16%). The quarter ended with a net loss of $5.1M, after a profit of $169.7M the previous quarter.
Operating cash flow was −$6.0M. Non-cash charges added back $11K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $2.5M.
Questions
What was Arbutus Biopharma's revenue in the second quarter 2026?
Arbutus Biopharma (ABUS) reported revenue of $1.0M for the second quarter 2026 (Q2 2026), -91% from a year earlier and -99% from the quarter before.
Was Arbutus Biopharma profitable in the second quarter 2026?
Operating loss was $6.0M (-588.2% of revenue) and net loss $5.1M.
Source: Arbutus Biopharma 10-Q on SEC EDGAR.